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Abstract
TNF receptor–associated factors (TRAFs) are multifunctional adaptor proteins involved in temporal and spatial coordination
of signals necessary for normal immune function. Here, we report that TRAF3, a TRAF family member with a key role in Toll-
like and TNF family receptor signaling and suppressor of lymphomagenesis, is post-translationally modified by the small
ubiquitin-related modifier (SUMO). Through yeast two-hybrid and co-immunoprecipitation assays we have identified Ubc9,
the SUMO conjugating enzyme, as a novel TRAF3-interacting protein. We show that Ubc9-dependent SUMOylation of
TRAF3 modulates optimal association with the CD40 receptor, thereby influencing TRAF3 degradation and non-canonical
NF-kB activation upon CD40 triggering. Collectively, our findings describe a novel post-translational modification of a TRAF
family member and reveal a link between SUMOylation and TRAF-mediated signal transduction.
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Introduction
TNF receptor–associated factors (TRAFs) are multifunctional
intracellular proteins which participate in the recruitment and
activation of a plethora of protein kinases involved in immune and
death receptor signaling. Among the seven known mammalian
TRAFs, TRAF2, TRAF3 and TRAF6 have been extensively
studied as their ablation severely impairs Toll-like and TNF family
receptor signal transduction.
TRAF3 was originally identified as a molecule that binds the
cytoplasmic domains of the TNF receptor family member CD40
and the oncogenic Epstein-Barr virus-encoded latent membrane
protein 1 (LMP1) [1,2,3](reviewed in [4]). Subsequently, TRAF3
was shown to interact with the cytoplasmic tails of other TNF
receptor family members, such as lymphotoxinb-receptor (LTbR),
OX40, CD27, CD30, Herpes virus entry mediator and receptor
activator of NF-kB [5,6,7] and more recently to participate in
Toll-like receptor signaling and to regulate the production of pro-
inflammatory cytokines and type I interferons in response to a
variety of pathogen-associated molecular patterns [8,9]. The
participation of TRAF3 in signal transduction from diverse
receptors reflects its major immunological role in host defense.
Indeed, TRAF3 deficiency has been linked to lymphoid defects in
the mouse and increased susceptibility to herpes simplex virus-1
(HSV-1)-induced encephalitis (HSE) in humans [10,11].
The impact of TRAF3 deregulation extends to the pathogenesis
of malignancy. Inactivating mutations and loss of heterozygosity in
the TRAF3 locus have been reported in a significant proportion of
myeloma patients, suggesting that TRAF3 may function as a
tumor suppressor [12,13]. In line with this notion, we and
others have previously demonstrated that TRAF3 mediates the
anti-proliferative effects of CD40 and LTbR in transformed cell
lines [14,15] and that overexpressed TRAF3 inhibits the growth of
carcinoma [14] and myeloma cells [13].
The role of TRAF3 in disease pathogenesis has partly been
attributed to the engagement of the ‘alternative’ NF-kB pathway
which involves the processing of p100 NF-kB2 to p52. In the
absence of stimulus, TRAF3 is required for the formation of a
cytoplasmic multi-protein complex containing TRAF2, NF-kB
inducing kinase (NIK) and the cellular inhibitors of apoptosis
(cIAP1/2). In this complex, the ubiquitin ligase activity of cIAPs is
channeled towards NIK leading to its degradation [16,17].
Indeed, ablation of TRAF3 in the mouse or reduced TRAF3
levels in myeloma [12,13] and HSE patients [18] elevate NIK
expression resulting in constitutive activation of the NF-kB2
pathway and accumulation of transcriptionally active p52.
Deregulated NF-kB2 signaling accounts for the postnatal lethality
associated with TRAF3 ablation [9].
Transient activation of p100 processing occurs in response to
stimulation of TRAF3-interacting receptors, such as CD40 [19].
Ligation of CD40 in B cells results in rapid recruitment of a
multiprotein complex containing TRAF2, TRAF3 and cIAP1/2
to the receptor. TRAF2 serves not only as adaptor protein but also
as E3 ubiquitin ligase which functions together with the E2
ubiquitin-conjugating enzyme Ubc13 to catalyze the addition of
lysine 63 (K63)–linked polyubiquitin chains to cIAP1/2. This, in
turn, activates the ubiquitin ligase activity of cIAP1/2 toward
TRAF3, catalyzing degradative K48–linked polyubiquitination.
The ensuing degradation of TRAF3 results in NIK accumulation
and activation through autophosphorylation [20]. Whereas
TRAF3 negatively regulates alternative NF-kB2 signaling, it is
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required for the activation of IRF3 and the interferon (IFN)
response, an effect attributed to K63 rather than K48-mediated
Ub linkages [20].
The function of TRAFs in signal transduction exceeds,
therefore, their role as molecular bridges between receptors and
intracellular signaling components and includes active regulation
of kinase activation through inducible ubiquitination. In this study
using yeast two-hybrid cloning and co-immunoprecipitation assays
we have identified Ubc9 as a novel TRAF3-interacting protein
and demonstrated that TRAF3 is subject to an additional post-
translational modification, namely SUMOylation. Furthermore,
we show that the TRAF3:Ubc9 association affects the ability of




TRAF3 cloned into the GAL4 DNA-binding vector pAS1 was
kindly provided by Professor George Mosialos (Aristotle University
of Thessaloniki, Greece) and used as bait in a two-hybrid screening
of HeLa cDNA library according to the Matchmaker Two-hybrid
System Protocol (Clontech). Positive clones were recovered and
sequenced. Interactions with Ubc9 were confirmed by transfection
into the S. cerevisiae strain PJ69-4A and examination of growth in
media lacking tryptophan and leucine (to select for the introduced
plasmids) and also lacking either adenine (SD-leu-trp-ade),
histidine but supplemented with 10 mM 3-aminotriazole (SD-
leu-trp-his + 10 mM 3-AT) or containing X-gal (SD-leu-trp +
40 mg/ml X-gal) to assay galactosidase reporter gene expression.
Cell culture and transfections
EJ cells [28] were maintained in RPMI medium supplemented
with 10% fetal bovine serum. 293T, a variant of the human
embryonic kidney cell line 293 (ATCC, CRL3216) and HeLa
cells stably expressing His-SUMO-1 and His-SUMO-2 (kindly
provided by Prof. Ron Hay, University of Dundee, UK, [21]),
were maintained in Dulbecco’s modified Eagle’s Medium
(DMEM, Gibco) supplemented with 10% fetal calf serum in an
atmosphere of 5% CO2, at 37uC. Transient transfections were
performed using Lipofectamine (Invitrogen) according to the
manufacturer’s protocol. Isolation of primary splenocytes was
performed as previously described [19].
Plasmids
SUMO expression vectors were gift from Prof. Ron Hay.
Human wild type Ubc9 was PCR amplified from a HeLa cDNA
library using Expand High Fidelity PCR System (Roche,
Germany) and the following primers: sense Bam-UBC-FORW
59-CTTTGAACGGATCCGGGATCGCCCTC- 39 and anti-
sense Eco-UBC-REV 59- CACAAGGTGAATTCTTAT-
GAGGGCGCAAAC- 39 (MWG, Germany). The PCR amplifi-
cation conditions were as follows: 94uC for 3 minutes followed by
29 cycles of 94 uC for 30 seconds, 64uC for 40 seconds and 72uC
for 45 seconds and a final extension step of 72uC for 5 minutes. A
mutated Ubc9 carrying a substitution of Cys93 in the active site of
the enzyme with Ala which is unable to form SUMO conjugates
was provided by Dr Y.Y. Mo [22]. TRAF3 deletion mutants
corresponding to aa 1-266 (Mutant 1), aa 1-376 (Mutant 2), aa
267-568 (mutant 3) and aa 346-568 (mutant 4) were generated by












Figure 1. TRAF3 interacts with Ubc9 in a yeast 2-hybrid assay. (A) S. cerevisiae strain PJ69-4A was transformed with plasmids expressing the
GAL4 activation domain (AD) fused to Ubc9, the GAL4 binding domain (BD) fused to TRAF3 or with control empty vectors in all possible
combinations. Cells were grown on standard medium (SD-leu-trp) in the presence or absence of X gal (SD-leu-trp+X gal), medium lacking adenine
(SD-leu-trp-ade) to detect expression of the GAL-ADE2 reporter gene or medium lacking histidine (SD-leu-trp-his + 5 mM 3-AT) to detect expression of
the GAL-HIS3 reporter gene. (B) Quantification of galactosidase reporter activity in yeast transformed with the vectors described in (A). Results shown
represent the mean values of galactosidase activity (6SD) relative to controls from 4 independent experiments.
doi:10.1371/journal.pone.0080470.g001
Post-Translational Modification of TRAF3 by SUMO
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e80470
Mutant 4R: 59 CCTCGAGTCAGGGATCGGGCAG 39
PCR conditions were as follows: for mutant 1 and 4, 94uC for 2
minutes followed by 30 cycles of 94 uC for 30 seconds, 61uC for 40
seconds and 72uC for 50 seconds and then extended by 72uC for
10 minutes; for mutants 2 and 3, 94uC for 2 minutes followed by
30 cycles of 94 uC for 30 seconds, 61uC for 40 seconds and 72uC
for 67 seconds and then extended by 72uC for 10 minutes. The
TRAF3 mutants were cloned as EcoRI/XhoI fragments into a
modified pcDNA3.1 (Invitrogen, CA, USA) vector containing a
FLAG-tag and sequenced.
Preparation of protein extracts
Depending on the experimental setting, cells were lysed in
different buffers. For native immunoprecipitations, cells were lysed
in RIPA buffer (25 mM Tris-HCI pH 7.2, 50 mM NaCI, 0.5%
NP40, 0.5% sodium deoxycholate) supplemented with 1% SDS
and 25 mM N-Ethylmaleimide or iodoacetamide (Sigma). Alter-
natively, cells were lysed in Guanidinium-HCI to allow purifica-
tion on Ni-NTA columns [21].
Co-Immunoprecipitation Studies
Cell lysates were cleared and incubated with anti-TRAF3
antibody (1 mg/mg lysate) and G-Sepharose Beads (20 ml) for
12 hours at 4uC on a rotor. The beads were washed extensively in
Lysis Buffer A [23] and boiled with 30 ml Protein Loading Buffer
[50 mM Tris pH 6.8, 4% SDS (w/v), 10% glycerol, 5%
mercaptoethanol, 0.01% bromophenol blue (w/v)].
Western Analysis
Samples were analyzed by SDS-PAGE and transferred onto
polyvinylidenedifluoride membrane (0.45 mM; Millipore). The
membranes were incubated with primary antibodies overnight at
4uC: TRAF3 (C20), TRAF2 (C20), IkBa (C21), RIP1 (C20) were
purchased from Santa-Cruz Biotechnology), anti-myc tag 9E10,
anti-FLAG M2 and b-actin antibodies were from Sigma and NF-
kB2 antibody from Cell Signaling Technology. Anti-SUMO-1 and
SUMO-2 antibodies were kindly provided by Professor Ron Hay,
University of Dundee, UK. Following 1 h incubation with the
appropriate secondary antibody, membranes were subjected to
enhanced chemiluminescence analysis.
GST Pull-Down Assays
Isolation and purification of GST or GST-Ubc9 fusion protein
were performed as previously described [23]. For pull-down
assays, 500 mg total protein isolated from HEK293 cells was mixed
with beads carrying GST or GST-Ubc9 and incubated for 2 h at
Figure 2. TRAF3interacts with Ubc9 through its ring finger TRAF-N domain. (A) GST-Ubc9 produced in bacteria as fusion with GST interacts
with FLAG-tagged TRAF3 expressed in HEK 293 cells. GST or GST-Ubc9 was incubated with protein lysates isolated from FLAG-TRAF3 transfected
HEK293 cells. Pulled-down proteins were solubilized in SDS protein sample buffer, separated on 8% SDS polyacrylamide gels and immunoblotted for
TRAF3. Coomassie blue staining was used to confirm equal utilization of GST and GST-Ubc9 proteins in the pull-down assays. (B) Ubc9 and TRAF3
interact in vivo. FLAG-tagged TRAF3 was co-expressed with myc-tagged Ubc9 in HEK293 cells. Ubc9 was detected in anti-FLAG immunoprecipitates.
As positive control [25], FLAG-tagged SMAD4 was used to monitor interactions with Ubc9. (C &D) Interaction of TRAF3 deletion mutants with Ubc9 in
an in vitro GST pull-down assay. 293T cells were transiently transfected with the FLAG-tagged TRAF3 deletion mutants shown in C. Thirty six hours
later, the extracts were incubated with purified GST-Ubc9 bound to glutathione sepharose beads. Interacting proteins were fractionated by SDS-
PAGE and immunoblotted with anti-FLAG mAb (lanes 1-5; D). Whole cell lysates (30 mg) were analyzed in parallel to monitor the motility of the TRAF3
deletion mutant proteins (lanes 6-10). I.P.; immunoprecipitation. I.B.; immunoblot. WCL; Whole cell lysates
doi:10.1371/journal.pone.0080470.g002
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4uC. After three washes with PBS, proteins were solubilized in 16
SDS protein sample buffer and separated in 8% SDS polyacryl-
amide gels.
Results
Isolation of Ubc9 as a TRAF3-interacting protein in yeast
To increase our understanding of the function of TRAF3, we
performed yeast two-hybrid interaction assays to search for
proteins that directly associate with TRAF3. An expression vector
in which full-length TRAF3 was fused to the Gal4 DNA binding
domain was used as bait to screen a HeLa cDNA library [24].
From approximately 10 million transformants, 10 independent
positive clones were obtained. One of them encoded the full-length
Ubc9, a protein associated with the process of SUMOylation.
To verify this interaction, S. cerevisiae strain PJ69-4A was
transformed with plasmids expressing the GAL4 activation
domain (AD) fused to Ubc9, the GAL4 binding domain (BD)
fused to TRAF3 or with control empty vectors in all possible
combinations. Cells were grown in standard medium (SD-leu-trp)
in the presence or absence of X gal, in medium lacking adenine
(SD-leu-trp-ade) to detect expression of the GAL-ADE2 reporter
gene or in medium lacking histidine (SD-leu-trp-his + 3-AT) to
detect expression of the GAL-HIS3 reporter gene. The growth
patterns of the transformed cells and the expression levels of b-
galactosidase activity confirmed that TRAF3 and Ubc9 interact in
yeast (Fig. 1).
TRAF3 associates with Ubc9 through its ring finger TRAF-
N domain
To further validate the interaction between Ubc9 and TRAF3,
a fusion of GST with Ubc9 was examined for its ability to interact
with FLAG-tagged TRAF3 expressed in human embryonic kidney
(HEK) 293 cells. As shown in Figure 2A, GST-Ubc9 strongly
associated with TRAF3 whereas control GST did not. This
interaction was further analyzed in mammalian cell co-immuno-
precipitation assays. The full-length Ubc9 construct containing an
N-terminal Myc epitope tag (myc-Ubc9) was transiently co-
expressed in HEK 293 cells with FLAG-tagged TRAF3 or, as
positive control, SMAD4 [25]. Cell lysates were immunoprecip-
itated using a monoclonal antibody against the FLAG epitope,
and co-precipitating Ubc9 was detected by immunoblotting with
Figure 3. TRAF3 is post-translationally modified by SUMO. (A) HeLa cells stably expressing His-tagged SUMO-1 or SUMO-2 and parental cells
were lysed in a protein-denaturing buffer and lysates were subjected to enrichment of SUMOylated proteins on nickel-nitrilotriacetic acid (Ni-NTA)
columns. Eluates were immunoblotted with a TRAF3 polyclonal antibody. (B & C) SUMO-1 modification of TRAF3. Protein lysates were obtained from
EJ bladder carcinoma, BJAB lymphoma and HeLa cervical carcinoma cells stably transfected with SUMO-1 (B) or mouse splenocytes (C) in the
presence or absence of iodocetamide (IDO) and immunoprecipitated (I.P) with anti-TRAF3 C20 antibody. The SUMO-1 conjugates were detected by
anti-SUMO-1 specific antibody. (D) SUMO-2/3 modification of TRAF3. Protein lysates were obtained from EJ cells in the presence orabsence of IDA
and TRAF3 immunoprecipitates (I.P) were immunoblotted (I.B) with an anti-SUMO-2/3 specific antibody.
doi:10.1371/journal.pone.0080470.g003
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anti-Myc polyclonal antibody. As shown in Figure 2B, FLAG-
TRAF3 interacted with Myc-Ubc9.
TRAF3 contains a N-terminal ring finger domain followed by
several zinc fingers [3]. The C-terminal half of TRAF3 comprises
the TRAF domain, which is conserved among all members of the
TRAF family and can be further subdivided into the TRAF-N and
TRAF-C regions [1]. To identify the TRAF3 domain which
contributes to Ubc9 binding, various FLAG-tagged TRAF3
deletion mutants were generated (Fig. 2C) and assayed for
association with GST-Ubc9. The results of the GST pull-down
assays demonstrated that the TRAF-N domain of TRAF3 is
predominantly responsible for binding to Ubc9 (Fig. 2D).
However, binding was reduced compared to wild-type TRAF3
indicating conformational effects on effective interaction with
Ubc9.
Ubc9 is required for SUMO modification of TRAF3
Similar to ubiquitin, SUMO is covalently conjugated to a
substrate protein lysine through a reaction that utilizes an
activating E1 enzyme, a conjugating E2 enzyme and an E3 ligase.
Unlike the ubiquitination pathway where each E2 has a specific set
of target proteins, SUMO conjugation is mediated exclusively by
Ubc9. The association of TRAF3 with Ubc9 (Fig. 1 and 2) led us
to postulate that TRAF3 is a SUMO substrate. In vertebrates, two
SUMO protein subfamilies, SUMO-1 and SUMO-2/3 have
mostly been studied. SUMO-2 and SUMO-3 are commonly
referred to as SUMO-2/3 due to 98% sequence similarity and the
lack, to date, of distinguishable functional differences.
HeLa cells stably expressing His-tagged SUMO-1 or SUMO-2
and parental cells were lysed in denaturing conditions to protect
SUMO conjugation from the action of SUMO-deconjugating
enzymes and lysates were subjected to enrichment of SUMOy-
lated proteins on nickel-nitrilotriacetic acid (Ni-NTA) columns.
Eluates were immunoblotted with a-TRAF3 polyclonal antibody.
The results showed immunoreactive bands with increased
molecular mass corresponding to endogenous TRAF3-SUMO
conjugates in eluates from both His-SUMO-1 and SUMO-2-
expressing HeLa clones (Fig. 3A).
To further validate this finding, lysates from EJ bladder
carcinoma, BJAB lymphoma and HeLa/His-SUMO-1 cervical
Figure 4. TRAF3 SUMOylation is Ubc9-dependent.(A) Over-expression of ‘‘dominant-negative’’ Ubc9C93A which is unable to catalyze formation
of SUMO conjugates reduces endogenous TRAF3 SUMOylation. HEK293 cells were transfected with Ubc9C93A and lysates were obtained using an IDO-
containing lysis buffer. Anti-TRAF3 immunoprecipitates (I.P) were immunoblotted (I.B) with either anti-SUMO-1 or anti-SUMO-2/3 antibodies, as
indicated. Lysates were also immunoblotted with anti-MYC tag antibody to confirm expression of Ubc9C93A or anti-TRAF3 to detect the levels of
immunoprecipitated endogenous TRAF3. CV; control vector. (B) Knock-down of Ubc9 diminishes TRAF3 SUMOylation. HEK 293 cells were transfected
with Ubc9 siRNA or an unrelated siRNA targeting luciferase (Luc) prior to lysis. Anti-TRAF3 immunoprecipitates were then immunoblotted with either
anti-SUMO-1 or anti-SUMO-2 antibodies, as indicated. Results are representative of at least 4 independent experiments for (A) and (B).
doi:10.1371/journal.pone.0080470.g004
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carcinoma cells were immunoprecipitated with anti-TRAF3 and
precipitates were immunoblotted with anti-SUMO-1 antibody.
Using normal lysis conditions we were unable to detect TRAF3-
SUMO-1 conjugates (Fig. 3B, lanes 2, 4 and 6). As SUMOylation
is readily reversible, we included the cysteine peptidase inhibitor
iodoacetamide (IDO) in the lysis buffer which inhibits SUMO-
deconjugating enzymes thus facilitating detection of SUMOylated
proteins. Addition of IDO allowed detection of higher molecular
weight bands representing SUMO-1-modified TRAF3 (Fig. 3B,
lanes 1, 3 and 5). Similar results were obtained by analyzing lysates
from mouse splenocytes, suggesting that SUMO-1 modification of
TRAF3 is not a phenomenon restricted to transformed cells (Fig.
3C). TRAF3 was also found to be substrate for SUMO-2/3 in EJ
cells (Fig. 3D).
To validate the link between Ubc9 and TRAF3 SUMOylation,
we targeted Ubc9 in HEK 293 cells by either over-expressing a
‘dominant negative’ mutant or by RNA interference (RNAi). The
mutated Ubc9 used in these experiments, Ubc9C93A, carries a
substitution of Cys93 with Ala in the active site of the enzyme
which renders it unable to catalyze formation of SUMO
conjugates [22]. Endogenous TRAF3 was immunoprecipitated
from cell lysates using an anti-TRAF3 polyclonal antibody and
immunoblotted with anti-SUMO-1 or anti-SUMO-2/3 antibod-
ies. As shown in Figure 4A, immunoreactive bands corresponding
to TRAF3-SUMO conjugates were detected in control-transfected
HEK 293 cell immunoprecipitates but their intensity was reduced
in the presence of dominant negative Ubc9. Similarly, the RNAi-
mediated knock-down of Ubc9 in EJ cells also led to significant
reduction in the levels of SUMOylated TRAF3 (Fig. 4B). These
data underscore the functional significance of the TRAF3:Ubc9
interaction in the SUMO modification of TRAF3.
Ubc9 is required for efficient TRAF3 degradation
following CD40 receptor occupancy
TRAF3 directly interacts with and participates in CD40
signaling. In particular, CD40 activation in B cells results in
cIAP-mediated ubiquitination and degradation of TRAF3 [26,27]
which is required for NIK stabilization and non-canonical NF-kB2
signal activation [16,17]. We have examined the impact of Ubc9
ablation on CD40-mediated TRAF3 degradation in EJ cells, a cell
line that was fundamental in the discovery of CD40 [28] and
functionally responds to CD40 receptor occupancy [29]. As shown
in Figure 5A, EJ cells transfected with control siRNA showed
progressive loss of TRAF3 upon CD40 stimulation whereas the
knock-down of endogenous Ubc9 attenuated this effect. As
control, the levels of cIAP2, a known CD40 ligand (CD154)-
inducible gene [30,31] did not differ between control and Ubc9
siRNA-transfected cells stimulated with recombinant CD154 (Fig.
5A).
Previous work has demonstrated that the TRAF3 gene encodes
different isoforms [32]. The identity of the two immunoreactive
bands detected by the anti-TRAF3 polyclonal antibody in Figure
5A was verified by RNAi. It was found that transfection of EJ cells
with TRAF3 siRNAs diminished the expression of the higher
molecular weight and reduced the intensity of the low molecular
weight protein whereas siRNA targeting the RIP1 kinase or an
unrelated siRNA targeting luciferase had no effect (Fig. 5B). In
agreement with the established link between TRAF3 and non-
canonical NF-kB signaling [16,17], the attenuated levels of
Figure 5. SUMOylation affects TRAF3 degradation and non-canonical NF-kB2 signaling in CD40-stimulated cells. (A) Knock-down of
Ubc9 diminishes CD40 ligand (CD154) induced TRAF3 degradation. EJ cells were transfected with Ubc9 siRNA or an unrelated siRNA targeting
luciferase (Luc) prior to stimulation with 0,5 mg/ml recombinant CD154 and lysis. Lysates were immunoblotted with anti-TRAF3, anti-cIAP2 or anti-b-
actin antibodies. Results are representative of at least 5 independent experiments. (B) Validation of siRNA targeting TRAF3. EJ bladder carcinoma cells
were transfected with siRNAs against TRAF3, RIP1 or the unrelated luciferase and knock-down efficacy and specificity were determined by
immunoblotting cell lysates with anti-TRAF3, RIP1 or b-actin antibodies. (C) Lysates from Ubc9 knocked-down cells were immunoblotted with anti-
NF-kB2 mAb recognizing both the full-length p100 and processed p52 form of NF-kB2 or with b-actin as loading control. Results are representative of
3 independent experiments. (D) Nuclear and cytoplasmic protein extracts were prepared from control and Ubc9 siRNA-transfected EJ cells before and
after stimulation with 0,5 mg/ml CD40L and analyzed for p65/RelA expression by immunoblot. The transcription factor Sp1 was used as a marker for
the purity of the nuclear cell extract preparation. Results are representative of 3 independent experiments.
doi:10.1371/journal.pone.0080470.g005
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TRAF3 in Ubc9-ablated EJ cells correlated with reduced p100
NF-kB2 processing upon CD40 stimulation (Fig. 5C). In contrast,
activation of the canonical NF-kB pathway, as determined by the
extent of nuclear translocation of the p65/RelA NF-kB subunit
following CD40 activation was similar between Ubc9 and control
siRNA-transfected cells (Fig. 5D).
SUMOylation increases the CD40-interacting capacity of
TRAF3
SUMOylation may influence the ability of a modified substrate
to interact with partner proteins. Given that CD40 ligation does
not effectively induce TRAF3 degradation following Ubc9 knock-
down, we surmised that TRAF3 SUMOylation may affect the
interaction of TRAF3 with CD40. To address this hypothesis, the
CD40 cytoplasmic tail (CT, Fig. 6A) was produced as fusion with
GST in bacteria and incubated with lysates from HEK293 cells in
the presence or absence of iodoacetamide (see Fig. 3B). GST pull-
downs demonstrated that CD40 strongly interacts with TRAF3 in
the presence of IDO but association is reduced in the absence of
SUMO protease inhibitor (Fig. 6A). As control, CD40 carrying a
Thr254Ala mutation (CTA) known to abolish interactions with
TRAF3 [3] failed to bind TRAF3 irrespective of IDO treatment.
To further validate this finding, a ‘‘dominant-negative’’
Ubc9C93A was over-expressed in HEK293 cells and lysates were
incubated, in the presence of IDO, with GST-CD40CT or GST-
CD40CTA bound to glutathione sepharose beads. Interacting
proteins were fractionated by SDS-PAGE and immunoblotted
with anti-TRAF3. Compared to vector-transfected cultures,
Ubc9C93A reduced binding of TRAF3 to CD40.
Discussion
TRAF3 is increasingly recognized as key mediator of inflam-
matory and oncogenic signal transduction. The pleiotropic
functions of TRAF3 largely depend on its ubiquitination status
with K63-mediated Ub linkages regulating the activation of IRF3
and the IFN response and degradative K48-mediated ubiquitina-
tion being required for CD40-induced non-canonical NF-kB2
signaling [20]. Results presented in this study demonstrate that
TRAF3 is subject to an additional post-translational modification,
SUMOylation, through its direct interaction with the SUMO
conjugating enzyme Ubc9. In particular, we have found TRAF3
to be modified by both SUMO-1 and SUMO-2/3. SUMO-2/3
can be conjugated to target proteins in a chain-wise fashion due to
internal SUMO conjugation motifs, whereas SUMO-1 lacks this
ability and often acts as a chain terminator [33,34]. It is thus likely
that TRAF3 is modified by mixed SUMO-2/3 and SUMO-1
proteins with SUMO-1 ‘‘capping’’ and terminating SUMO-2/3
chains. The possibility that mono-SUMOylation also occurs
requires evaluation particularly as TRAF3 contains numerous
Lys residues which may serve as targets for SUMO modification.
A crosstalk between SUMOylation and ubiquitination has
recently been suggested on the basis of co-purification of
SUMO2/3 and ubiquitin conjugates and the accumulation of
SUMO2/3 conjugates in cells treated with the proteasomal
inhibitor MG132 [34,35,36,37]. Whilst clear evidence that
SUMO and ubiquitin are linked to one another in the same
chain has still to be determined, the reported findings show that
SUMO2/3-modified proteins may be ubiquitinated and targeted
for proteasomal degradation [35]. Indeed, once poly-SUMOy-
lated, the promyelocytic leukemia (PML) protein recruits the
ubiquitin ligase RING finger protein 4 (RNF4) [38,39] which
elongates the SUMO chains by adding ubiquitin moieties to them.
This, in turn, results in proteasomal degradation of PML [39].
SUMOylation has also been reported to positively modulate
ubiquitination of the Williams-Beuren syndrome protein
GTF2IRD1 [40]. Data shown in the present study provide
additional support for the association between these post-
translational modifications by demonstrating that Ubc9 knock-
down significantly reduces CD40-mediated TRAF3 degradation
and NF-kB2 processing. Despite the established role of ubiquitina-
tion in TRAF3 signal transduction [20,41], the Lys residues
targeted for ubiquitin conjugation remain unknown and further
studies are required to elucidate whether TRAF3 SUMOylation
Figure 6. TRAF3 SUMOylation affects its CD40-interacting
capacity. (A) The binding of TRAF3 to GST-CD40CT increases when
SUMO modification is maintained. HEK293 cells were lysed in the
presence or absence of iodoacetamide (IDO) and lysates were
incubated with bacterially produced GST-CD40 C-terminus (CT) or, as
control GST-CD40CTA, carrying a T254RA mutation (GST-CD40CTA)
which abolishes interaction with TRAF3, bound to glutathione
sepharose beads. Interacting proteins were fractionated by SDS-PAGE
and immunoblotted (I.B.) with anti-TRAF3 Ab. Whole cell lysates (WCL;
30 mg) were analyzed by immunoblot for TRAF3 expression levels.
Lower right panel: Coomassie-stained gel showing GST-CD40CT and
GST-CD40CTA produced in bacteria. (B) Over-expression of ‘‘dominant-
negative’’ Ubc9C93A reduces binding of TRAF3 to CD40. HEK293 cells
were transfected with Ubc9C93A or control vector (CV), lysates were
obtained using an IDO-containing lysis buffer and incubated with GST-
CD40CT or GST-CD40CTA bound to glutathione sepharose beads.
Interacting proteins were fractionated by SDS-PAGE and immuno-
blotted (I.B.) with anti-TRAF3. Whole cell lysates (WCL; 30 mg) were
analyzed for TRAF3 and Ubc9C93A expression levels by immunoblotting
using anti-TRAF3 and Myc tag Abs, respectively. Results in (A) & (B) are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0080470.g006
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affects proteasomal recognition and if substrates modified by the
two types of conjugates can be degraded.
Protein modification by SUMOylation can have different
outcomes including conformational changes and interactions with
other proteins [36,37]. Data presented in this paper show that
SUMO modification of TRAF3 influences its CD40-interacting
capacity. CD40 may exert opposing phenotypic effects on normal
versus malignant cells [42]. The finding that TRAF3 is subject to
SUMO modification irrespective of the transformation status of
the cell (Fig. 3) indicates a broad role for TRAF3 SUMOylation in
CD40-mediated NF-kB2 signal transduction.
On the basis of these observations we propose that SUMO-
modified TRAF3 represents a pool of TRAF3 ‘primed’ for CD40
binding and stimulus-dependent ubiquitination and degradation.
As TRAF3 is SUMOylated in the absence of stimulus (Fig. 3), we
surmised that SUMOylation may also affect basal TRAF3
turnover. Indeed, semi-quantitative assessment of TRAF3 expres-
sion in EJ and HEK293 cells transfected with Ubc9 siRNA
demonstrated elevated basal levels of TRAF3 (Fig. S1). Given the
important functional roles attributed to TRAF3 [12-16], our
findings may shed new light into the molecular pathways
regulating TRAF3 function and signal transduction.
Supporting Information
Figure S1 Ubc9 regulates the basal levels of TRAF3. EJ
and HEK293 cells were transfected with Ubc9 siRNA or an
unrelated siRNA targeting luciferase (Luc). Lysates (20 mg) were
immunoblotted with anti-TRAF3, Ubc9 or b-actin antibodies, as
indicated. Results are representative of 5 independent experi-
ments. Semi-quantitation of TRAF3 expression was performed
using Image J (http://rsbweb.nih.gov/ij/).
(TIF)
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